Skip to main content
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc. — Investor Relations & Filings

Ticker · ACRS ISIN · US00461U1051 LEI · 5493000B2LQ9QTW1DF52 US Manufacturing
Open in API
Filings indexed 844 across all filing types
Latest filing 2023-04-10 Proxy Solicitation & In…
Country US United States of America
Listing US ACRS

About Aclaris Therapeutics, Inc.

https://www.aclaristx.com/

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel drug candidates for immuno-inflammatory diseases. The company leverages its core expertise in drug discovery, development, and kinase inhibition to create a pipeline of both small and large molecule drugs. Aclaris focuses on translating scientific discovery into innovative therapies to address the needs of patients with underserved conditions.

Recent filings

Filing Released Lang Actions
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC for the 2023 Annual Meeting of Stockholders of Aclaris Therapeutics, Inc. It includes detailed information about the meeting agenda, voting procedures, director nominations, executive compensation advisory vote, amendment to the certificate of incorporation, and auditor ratification. The document is not a full annual report or financial statement but is a solicitation of shareholder votes and information related to the annual meeting. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is substantial (15,000 characters), indicating it is the full proxy statement, not just an announcement. Therefore, the correct classification is PSI with high confidence.
2023-04-10 English
SEC SCHEDULE 13G
Major Shareholding Notification
2023-04-10 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 30, 2023, reporting the sale of 3.4 million shares of common stock for $27.5 million. The content focuses on a capital raising transaction and does not contain financial statements or detailed financial analysis. It is a current report disclosing a financing event. According to the filing definitions, updates on company fundraising or capital structure changes fall under Capital/Financing Update (CAP). The document length is under 5,000 characters and contains substantive information about the financing event, so it is not merely an announcement of a report. Therefore, the appropriate classification is CAP.
2023-03-31 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details an amendment to a consulting services agreement with a former CFO, including terms of the amendment and related equity award vesting. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is primarily an announcement of a management-related event (departure and consulting agreement amendment with a former officer). Therefore, it fits best under Board/Management Information (MANG). The document length is 4284 characters, which is typical for an 8-K filing of this nature and not a full report. Hence, the classification is MANG with high confidence.
2023-03-27 English
FORM 4 SUBMISSION
Director's Dealing
2023-03-17 English
SCHEDULE 13G
Major Shareholding Notification
2023-03-16 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.